Add like
Add dislike
Add to saved papers

Proteinuria and the Clinical Course of Dobrava-Belgrade Hantavirus Infection.

Nephron Extra 2018 January
Purpose: Human infection with Dobrava-Belgrade virus (DOBV) in Northern Germany causes a mild form of hantavirus disease predominantly characterized by acute kidney injury due to interstitial nephritis. We evaluated the largest number of DOBV-infected patients so far regarding clinical course, proteinuria, and prognostic markers.

Patients and Methods: Patients with DOBV-associated hantavirus disease admitted to the Renal Division of the University of Lübeck (Germany) between 1997 and 2012 were included in this study. Symptoms, clinical course, laboratory parameters, and urinary protein analysis were investigated at admission (baseline, t0 ), 3-5 days (t3-5 ), 10-17 days (t10-17 ), and after 1 year of follow-up (t365 ).

Results: Of the 34 patients (male/female ratio: 23/11; age: 41 ± 14 years) included in the study, 4 underwent hemodialysis (HD). Glomerular filtration rate was 17 ± 14 mL/min at t0 and increased to 27 ± 26 mL/min (t3-5 ), 57 ± 20 mL/min (t10-17 ), and 84 ± 16 mL/min (t365 ). Albuminuria and tubular proteinuria (α1 - and β2 -microglobulin) decreased during follow-up; the urinary α1 -microglobulin concentration in patients who required HD was significantly higher than that in patients not requiring HD (t0 : 186 ± 51 vs. 45 ± 26 mg/g creatinine; t3-5 : 87 ± 14 vs. 32 ± 16 mg/g creatinine; t10-17 : 63 ± 18 vs. 28 ± 12 mg/g creatinine; p < 0.001).

Conclusions: DOBV infection of inpatients in Northern Germany is associated with severe kidney injury that recovers within a few weeks and normalizes within 1 year. Tubular proteinuria is associated with the severity of kidney injury and the necessity of renal replacement therapy in these DOBV-infected patients.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app